Abstract
Lactobacilli have previously been used to deliver vaccine components for active immunization in vivo. Vectors encoding a single-chain Fv (scFv) antibody fragment, which recognizes the streptococcal antigen I/II (SAI/II) adhesion molecule of Streptococcus mutans, were constructed and expressed in Lactobacillus zeae (American Type Culture Collection (ATCC) 393). The scFv antibody fragments secreted into the supernatant or expressed on the surface of the bacteria showed binding activity against SAI/II in enzyme-linked immunosorbent assay (ELISA), and surface scFv-expressing lactobacilli agglutinated SAI/II-expressing S. mutans in vitro without affecting the corresponding SAI/II knockout strain. Lactobacilli expressing the scFv fragment fused to an E-tag were visualized by scanning electron microscopy (SEM) using beads coated with a monoclonal anti-E-tag antibody, and they bound directly to beads coated with SAI/II. After administration of scFv-expressing bacteria to a rat model of dental caries development, S. mutans bacteria counts and caries scores were markedly reduced. As lactobacilli are generally regarded as safe (GRAS) microorganisms, this approach may be of considerable commercial interest for in vivo immunotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout



Similar content being viewed by others
References
Krasse, B., Edwardsson, S., Svensson, I. & Trell, L. Implantation of caries-inducing streptococci in the human oral cavity. Arch. Oral Biol. 12, 231–236 (1967).
Krasse, B. & Carlsson, J. Various types of streptococci and experimental caries in hamsters. Arch. Oral Biol. 15, 25–32 (1970).
Lehner, T., Challacombe, S.J. & Caldwell, J. Immunologic basis for vaccination against dental caries in rhesus monkeys. J. Dent. Res. 55, C166–C180 (1976).
Loesche, W.J., Rowan, J., Straffon, L.H. & Loos, P.J. Association of Streptococcus mutants with human dental decay. Infect. Immun. 11, 1252–1260 (1975).
Russell, M.W. Immunization against dental caries. Curr. Opin. Dent. 2, 72–80 (1992).
Loesche, W.J. Role of Streptococcus mutans in human dental decay. Microbiol. Rev. 50, 353–380 (1986).
Michalek, S.M. et al. Protection of gnotobiotic rats against dental caries by passive immunization with bovine milk antibodies to Streptococcus mutans. Infect. Immun. 55, 2341–2347 (1987).
Hamada, S. et al. Oral passive immunization against dental caries in rats by use of hen egg yolk antibodies specific for cell-associated glucosyltransferase of Streptococcus mutans. Infect. Immun. 59, 4161–4167 (1991).
Filler, S.J., Gregory, R.L., Michalek, S.M., Katz, J. & McGhee, J.R. Effect of immune bovine milk on Streptococcus mutans in human dental plaque. Arch. Oral Biol. 36, 41–47 (1991).
Hatta, H. et al. Passive immunization against dental plaque formation in humans: effect of a mouth rinse containing egg yolk antibodies (IgY) specific to Streptococcus mutans. Caries Res. 31, 268–274 (1997).
Lehner, T., Caldwell, J. & Smith, R. Local passive immunization by monoclonal antibodies against streptococcal antigen I/II in the prevention of dental caries. Infect. Immun. 50, 796–799 (1985).
Lehner, T., Ma, J.K. & Kelly, C.G. A mechanism of passive immunization with monoclonal antibodies to a 185,000 M(r) streptococcal antigen. Adv. Exp. Med. Biol. 327, 151–163 (1992).
Ma, J.K., Smith, R. & Lehner, T. Use of monoclonal antibodies in local passive immunization to prevent colonization of human teeth by Streptococcus mutans. Infect. Immun. 55, 1274–1278 (1987).
Ma, J.K., Hunjan, M., Smith, R., Kelly, C. & Lehner, T. An investigation into the mechanism of protection by local passive immunization with monoclonal antibodies against Streptococcus mutans. Infect. Immun. 58, 3407–3414 (1990).
Ma, J.K. et al. Generation and assembly of secretory antibodies in plants. Science 268, 716–719 (1995).
Ma, J.K. et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat. Med. 4, 601–606 (1998).
Little, M., Kipriyanov, S.M., Le Gall, F. & Moldenhauer, G. Of mice and men: hybridoma and recombinant antibodies. Immunol. Today 21, 364–370 (2000).
Lorenzen, N. et al. Immunoprophylaxis in fish by injection of mouse antibody genes. Nat. Biotechnol. 18, 1177–1180 (2000).
Giddings, G., Allison, G., Brooks, D. & Carter, A. Transgenic plants as factories for biopharmaceuticals. Nat. Biotechnol. 18, 1151–1155 (2000).
Mottershead, D.G., Alfthan, K., Ojala, K., Takkinen, K. & Oker-Blom, C. Baculoviral display of functional scFv and synthetic IgG-binding domains. Biochem. Biophys. Res. Commun. 275, 84–90 (2000).
Lamarre, A., Yu, M.W., Chagnon, F. & Talbot, P.J. A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice. Eur. Immunol. 27, 3447–3455 (1997).
Magliani, W. et al. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat. Biotechnol. 15, 155–158 (1997).
Matthews, R., Hodgetts, S. & Burnie, J. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J. Infect. Dis. 171, 1668–1671 (1995).
de Vos, W.M. Gene expression systems for lactic acid bacteria. Curr. Opin. Microbiol. 2, 289–295 (1999).
Ahrne, S. et al. The normal Lactobacillus flora of healthy human rectal and oral mucosa. J. Appl. Microbiol. 85, 88–94 (1998).
Shornikova, A.V., Casas, I.A., Isolauri, E., Mykkanen, H. & Vesikari, T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J. Pediatr. Gastroenterol. Nutr. 24, 399–404 (1997).
Gionchetti, P., Rizzello, F., Venturi, A. & Campieri, M. Probiotics in infective diarrhea and inflammatory bowel diseases. J. Gastroenterol. Hepatol. 15, 489–493 (2000).
Guandalini, S. et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J. Pediatr. Gastroenterol. Nutr. 30, 54–60 (2000).
Vanderhoof, J.A. et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J. Pediatr. 135, 564–568 (1999).
Perdigon, G., de Macias, M.E., Alvarez, S., Oliver, G. & de Ruiz Holgado, A.P. Systemic augmentation of the immune response in mice by feeding fermented milks with Lactobacillus casei and Lactobacillus acidophilus. Immunology 63, 17–23 (1988).
Isolauri, E., Joensuu, J., Suomalainen, H., Luomala, M. & Vesikari, T. Improved immunogenicity of oral D × RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 13, 310–312 (1995).
Pouwels, P.H., Leer, R.J. & Boersma, W.J. The potential of Lactobacillus as a carrier for oral immunization: development and preliminary characterization of vector systems for targeted delivery of antigens. J. Biotechnol. 44, 183–192 (1996).
Pouwels, P.H. et al. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int. J. Food Microbiol. 41, 155–167 (1998).
Shaw, D.M. et al. Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. Immunology 100, 510–518 (2000).
Pouwels, P.H. et al. Lactobacilli as vehicles for targeting antigens to mucosal tissues by surface exposition of foreign antigens. Methods Enzymol. 336, 369–389 (2001).
Piard, J.C., Jimenez-Diaz, R., Fischetti, V.A., Ehrlich, S.D. & Gruss, A. The M6 protein of Streptococcus pyogenes and its potential as a tool to anchor biologically active molecules at the surface of lactic acid bacteria. Adv. Exp. Med. Biol. 418, 545–550 (1997).
Savijoki, K., Kahala, M. & Palva, A. High level heterologous protein production in Lactococcus and Lactobacillus using a new secretion system based on the Lactobacillus brevis S-layer signals. Gene 186, 255–262 (1997).
Eibl, M.M., Wolf, H.M., Furnkranz, H. & Rosenkranz, A. Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. N. Engl. J. Med. 319, 1–7 (1988).
Tjellström, B., Stenhammar, L., Eriksson, S. & Magnusson, K.E. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 341, 701–702 (1993).
Hammarström, V., Smith, C.I. & Hammarström, L. Oral immunoglobulin treatment in Campylobacter jejuni enteritis. Lancet 341, 1036 (1993).
Casswall, T.H. et al. Oral IgA-IgG treatment of chronic non-specific diarrhea in infants and children. Acta. Paediatr. 85, 1126–1128 (1996).
Weiner, C. et al. Passive immunity against human pathogens using bovine antibodies. Clin. Exp. Immunol. 116, 193–205 (1999).
Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352–1355 (2000).
Gunneriusson, E., Samuelson, P., Uhlen, M., Nygren, P.A. & Stahl, S. Surface display of a functional single-chain Fv antibody on staphylococci. J. Bacteriol. 178, 1341–1346 (1996).
Beninati, C. et al. Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat. Biotechnol. 18, 1060–1064 (2000).
Maassen, C.B. et al. Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Vaccine 17, 2117–2128 (1999).
Bleiweis, A.S., Lee, S.F., Brady, L.J., Progulske-Fox, A. & Crowley, P.J. Cloning and inactivation of the gene responsible for a major surface antigen on Streptococcus mutans. Arch. Oral Biol. 35, 15S–23S (1990).
Bowen, W.H., Pearson, S.K. & Young, D.A. The effect of desalivation on coronal and root surface caries in rats. J. Dent. Res. 67, 21–23 (1988).
Keyes, P.H. Dental caries in the molar teeth of rats. II. A method for diagnosing and scoring several types of lesions simultaneously. J. Dent. Res. 37, 1088–1099 (1958).
Acknowledgements
This work was supported by the Swedish Medical Research Council and by the Foundation for Preventive Caries Research (Patentmedelsfonden).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Krüger, C., Hu, Y., Pan, Q. et al. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol 20, 702–706 (2002). https://doi.org/10.1038/nbt0702-702
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1038/nbt0702-702
This article is cited by
-
Development of bacteria as diagnostics and therapeutics by genetic engineering
Journal of Microbiology (2019)
-
Purification-independent immunoreagents obtained by displaying nanobodies on bacteria surface
Applied Microbiology and Biotechnology (2019)
-
Engineering bacteria for diagnostic and therapeutic applications
Nature Reviews Microbiology (2018)
-
Development of a counterselectable seamless mutagenesis system in lactic acid bacteria
Microbial Cell Factories (2017)
-
Lactobacillus delivery of bioactive interleukin-22
Microbial Cell Factories (2017)


